NCT04021043View on ClinicalTrials.gov

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 19, 2019

Primary Completion Date

April 14, 2025

Study Completion Date

April 14, 2025

Conditions
Advanced Malignant Solid NeoplasmMetastatic Carcinoma in the LiverMetastatic Carcinoma in the LungMetastatic Malignant Neoplasm in the Thoracic CavityMetastatic Malignant Solid Neoplasm
Interventions
DRUG

Anti-GITR Agonistic Monoclonal Antibody BMS-986156

Given IV

BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

RADIATION

Stereotactic Body Radiation Therapy

Undergo SBRT

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT04021043 - BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers | Biotech Hunter | Biotech Hunter